Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

This article reviews primary cicatricial alopecias, focusing on lymphocytic forms such as chronic cutaneous lupus erythematosus, according to a classification by the North American Hair Research Society, and reports no new clinical results.

This review article highlights that mesotherapy, a popular non-surgical procedure in aesthetic dermatology, involves injecting a mixture of compounds into the skin for purposes like skin rejuvenation and hair loss treatment, but lacks large-scale studies on its efficacy and safety.

This chapter reviews differences in dermatological treatments and conditions between male and female patients, particularly noting the impacts of sex steroids on various skin processes, but presents no new clinical findings.

This article reviews the classifications and characteristics of androgenic alopecia and provides no new clinical results; it emphasizes the importance for aestheticians to understand current treatment evidence.

This review discusses the rationale for targeting 5α-reductase isoenzymes in prostate cancer prevention and treatment, highlighting the potential benefits of using inhibitors like dutasteride and finasteride but reports no new experimental results.

This review discusses recent therapeutic advances in treating various types of hair loss, including androgenetic alopecia, alopecia areata, frontal fibrosing alopecia, and hair transplant technologies, but reports no new clinical results.

Dutasteride is more effective than finasteride for hair growth, and pregabalin effectively treats neuropathic pain.

This article reviews the role and controversies of 5α-reductase inhibitors like finasteride and dutasteride in managing prostate cancer, without presenting new research results.

This review discusses the adverse effects of 5α-reductase inhibitors, finasteride and dutasteride, on sexual, psychological, and vascular health, emphasizing the need for physicians to inform patients of these risks.

This article reviews current knowledge on the causes, diagnosis, and medical treatments for androgenetic alopecia, particularly in men, and reports no new findings.

This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.

This review summarizes current and emerging treatments for common hair loss conditions, highlighting good evidence for androgenetic alopecia but noting the lack of long-term data for alopecia areata and cicatricial alopecias.

This review highlights current treatment options for frontal fibrosing alopecia, noting that 5-α-reductase inhibitors, intralesional steroids, and hydroxychloroquine have the highest evidence of effectiveness, while other therapies show variable results and need further research.

This review summarizes the current treatment modalities for frontal fibrosing alopecia and provides a practical guide for clinicians, but reports no new clinical results.

This meta-analysis found that the combination of topical minoxidil-finasteride was more effective than minoxidil alone in improving hair density, hair diameter, and global photographic assessment for male androgenetic alopecia, though larger standardized trials are needed to confirm long-term outcomes.

This review discusses current and emerging treatments for androgenetic alopecia, covering mechanisms, efficacy, and safety of both androgen-targeted and non-androgen-targeted approaches, but reports no new clinical results.

Hormonal treatments can help with hair loss, acne, and excess hair growth, but it takes 3-6 months to see results and patients should know the possible side effects.

Pharmacists play a crucial role in improving treatment outcomes and staying updated on various health conditions.

This review discusses various treatments for noncicatricial alopecias, such as androgenetic alopecia and alopecia areata, including mesotherapy, microneedling, and platelet-rich plasma therapy, noting that outcomes vary across these procedures.

This systematic review found that intralesional dutasteride treatments for androgenic alopecia in adults improved hair density and thickness with minimal adverse effects, although study methodologies varied and lacked large-scale trials.

This study clarifies the fundamental aspects of intradermotherapy or mesotherapy, tracing its historical development and highlighting its benefits as well as the negative consequences of improper use, specifically addressing its decline due to severe side effects from treatment errors.

This study found that in patients with female androgenetic alopecia, mesodermal injection of 0.5% minoxidil was more effective in increasing hair density and improving hairline height than topical 2% minoxidil, with comparable safety over 16 weeks.

This review reported that 5-alpha-reductase inhibitors were effective in stabilizing disease progression or reducing the rate of progression in some cases of frontal fibrosing alopecia, though evidence on safety remains limited.

This expert panel review developed consensus recommendations for managing androgenetic alopecia in Canadian adults, endorsing seven interventions like oral and topical medications and platelet-rich plasma.

In this study, analysis of FDA adverse event reports revealed that topical finasteride was associated with fewer post-finasteride syndrome-like adverse events than oral finasteride, but many reports lack critical data, suggesting caution in attributing causality.

This review indicates that while microneedling shows potential for managing androgenetic alopecia, particularly in combination with other treatments, the existing evidence is of low to moderate quality, and more robust trials are needed to confirm its clinical efficacy and safety.

This analysis of the Prostate Cancer Prevention Trial found that finasteride reduces prostate cancer risk by nearly 25% and enhances the PSA test's ability to detect prostate cancer and high-risk diseases.

This article highlights that hormonal changes during menopause can significantly affect hair health, leading to decreased hair density, altered texture, and increased hair disorders, which may subsequently impact emotional well-being in women.

This study suggests that low-dose oral minoxidil could be a safe and effective option for male and female-patterned hair loss, potentially benefiting those unable to tolerate topical treatments.